This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Nanjing Kaedi Biotherapeutics Ltd.. Active years: 2021-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Shanghai, CN (2021)
- Nanjing, CN (2022)
Company Filing History:
Years Active: 2021-2022
Title: Innovations of Hongjiu Dai in Cancer Treatment
Introduction
Hongjiu Dai is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of biotherapeutics, particularly in the development of chimeric antigen receptor (CAR) cells for cancer treatment. With a total of 3 patents, his work focuses on innovative methods to target cancer cells effectively.
Latest Patents
One of his latest patents is titled "Bi-specific targeting human NKG2DL and CLDN18A2 chimeric antigen receptor cells, preparation method and application thereof." This patent describes a CAR cell that bi-specifically targets human NKG2DL and CLDN18A2. The CAR includes a targeting human NKG2DL antigen domain, an anti-CLDN18A2 antigen binding domain, a hinge domain, a transmembrane domain, and an intracellular T cell signaling domain. The CAR can be utilized in methods for detecting cancer in mammals and for treating or preventing cancer.
Another significant patent is "Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof." This invention details a CAR cell specifically targeting human Claudin18.2 (CLDN18A2). The extracellular binding region of the CAR includes a protein that recognizes CLDN18A2, with specific amino acid sequences. The immune effector cell modified by this CAR can be employed in tumor treatment.
Career Highlights
Hongjiu Dai is currently associated with Nanjing Kaedi Biotherapeutics Ltd., where he continues to advance his research in cancer therapies. His work has garnered attention for its potential to improve treatment outcomes for cancer patients.
Collaborations
He collaborates with notable colleagues, including Jingjing Zhu and Hui Xu, who contribute to his research endeavors.
Conclusion
Hongjiu Dai's innovative work in the field of biotherapeutics, particularly through his patents on chimeric antigen receptors, showcases his commitment to advancing cancer treatment. His contributions are paving the way for new therapeutic strategies in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile